Bnp Paribas Asset Management Holding S.A. Denali Therapeutics Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 1,139 shares of DNLI stock, worth $18,656. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,139Holding current value
$18,656% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
251Shares Held
135MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$216 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$193 Million0.0% of portfolio
-
Baillie Gifford & CO11.6MShares$190 Million0.13% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$108 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$103 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.2B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...